Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(04): 420-426
DOI: 10.4103/ijmpo.ijmpo_202_15
Original Article

Prognostic Factors and Survival Outcomes of Intracranial Ependymoma Treated with Multimodality Approach

Kunhi Parambath Haresh
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Ajeet Kumar Gandhi
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Supriya Mallick
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Rony Benson
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Subhash Gupta
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Daya Nand Sharma
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Pramod Kumar Julka
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Goura Kisor Rath
Department of Radiation Oncology, Dr. B.R.A IRCH, All India Institute of Medical Sciences, New Delhi,, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Objectives: We aimed to analyze treatment outcomes of intracranial ependymoma (ICE) treated at our institute with multimodality approach. Materials and Methods: Demography, treatment details, and survival data of 40 patients (2005–2012) were collected in a predesigned pro forma. Kaplan Meier method was used to analyze disease-free survival (DFS) and the impact of prognostic factors was determined using univariate analysis (log-rank test). Multivariate analysis was performed using Cox-proportional hazard model. SPSS version 21.0 was used for all statistical analysis. Results: Male:female ratio was 29:11. Gross total resection: subtotal resection or less was 42.5%: 57.5%. A total of 16 patients (40%) had anaplastic histology. All except two patients received adjuvant radiotherapy. Four patients received concurrent chemotherapy (temozolomide [TMZ]) and 10 patients received adjuvant chemotherapy (6 carboplatin plus etoposide; 4 TMZ). Median follows up was 18 months (2–60 months). Median DFS for the entire cohort was 22.42 months. The estimated 1, 2, and 3 years DFS was found to be 58.5%, 41%, and 30.7%, respectively. On univariate analysis, patients receiving higher radiation dose (56 Gray vs. 60 Gray; hazard ratio [HR] 0.366; 95% confidence interval [CI] 0.142–0.9553; P = 0.02) and lower MIB labeling index (<20 vs. ≥20; HR 0.238; 95% CI 0.092–0.617; P = 0.001) had a better DFS. Higher radiation dose continued to be an independent prognostic factor on multivariate analysis (HR 0.212; 95% CI 0.064–0.856; P = 0.03). Conclusion: ICE has guarded prognosis. Adjuvant radiotherapy to a higher radiation dose improves survival. Higher MIB labeling index connotes a dismal survival despite the use of radiotherapy and chemotherapy.

Keywords

Chemotherapy - ependymoma - intracranial - radiation


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used forcommercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gondi V, Vogelbaum MA, Grimm S, Mehta MP. Primary intracranial neoplasm. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 669-70.
  • 2 Freeman CR, Farmer JP, Taylor RE. Central Nervous System Tumors in Children. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 1643-5.
  • 3 Salazar OM, Castro-Vita H, VanHoutte P, Rubin P, Aygun C. Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 1983;59:652-9.
  • 4 Goldwein JW, Corn BW, Finlay JL, Packer RJ, Rorke LB, Schut L. Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991;67:2766-71.
  • 5 Paulino AC. The local field in infratentorial ependymoma: Does the entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys 2001;49:757-61.
  • 6 Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol 2009;10:258-66.
  • 7 Timmermann B, Kortmann RD, Kühl J, Rutkowski S, Dieckmann K, Meisner C, et al. Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiother Oncol 2005;77:278-85.
  • 8 Needle MN, Goldwein JW, Grass J, Cnaan A, Bergman I, Molloy P, et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 1997;80:341-7.
  • 9 Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, et al. Amulticenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004;100:1221-9.
  • 10 Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
  • 11 Bailey P. A study of tumors arising from ependymal cells. Arch Neurol Psychiatry 1924;11:1-27.
  • 12 Rogers L, Pueschel J, Spetzler R, Shapiro W, Coons S, Thomas T, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005;102:629-36.
  • 13 Rousseau P, Habrand JL, Sarrazin D, Kalifa C, Terrier-Lacombe MJ, Rekacewicz C, et al. Treatment of intracranial ependymomas of children: Review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994;28:381-6.
  • 14 Massimino M, Gandola L, Giangaspero F, Sandri A, Valagussa P, Perilongo G, et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: Final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys 2004;58:1336-45.
  • 15 White L, Kellie S, Gray E, Toogood I, Waters K, Lockwood L, et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG). J Pediatr Hematol Oncol 1998;20:125-30.
  • 16 Duffner PK, Krischer JP, Sanford RA, Horowitz ME, Burger PC, Cohen ME, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998;28:215-22.
  • 17 Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319-29.
  • 18 Foreman NK, Love S, Gill SS, Coakham HB. Second-look surgery for incompletely resected fourth ventricle ependymomas: Technical case report. Neurosurgery 1997;40:856-60.
  • 19 Bouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 2012;83:1541-8.
  • 20 Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 2008;71:87-97.
  • 21 Murai T, Sato K, Iwabuchi M, Manabe Y, Ogino H, Iwata H, et al. Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. Jpn J Radiol 2016;34:211-8.
  • 22 Ares C, Albertini F, Frei-Welte M, Bolsi A, Grotzer MA, Goitein G, et al. Pencil beam scanning proton therapy for pediatric intracranial ependymoma. J Neurooncol 2016;128:137-45.
  • 23 Eaton BR, Chowdhry V, Weaver K, Liu L, Ebb D, MacDonald SM, et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. Radiother Oncol 2015;116:301-8.
  • 24 Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 2009;25:1293-301.
  • 25 Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011;20:143-57.
  • 26 Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across all CNScompartments, histopathological grades, and age groups. Cancer Cell 2015;27:728-43.
  • 27 Benson R, Mallick S, Julka PK, Rath GK. Molecular predictive and prognostic factors in ependymoma. Neurol India 2016;64:279-86.